Get the Stockscreener App
137.34
0.09%
0.13
Pre-market:
137.88
0.54
+0.39%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $137.34, with a volume of 7.36M.
It is up +0.09% in the last 24 hours and down -8.34% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$137.21
Open:
$139.675
24h Volume:
7.36M
Relative Volume:
1.02
Market Cap:
$170.50B
Revenue:
$29.45B
Net Income/Loss:
$8.51B
P/E Ratio:
20.25
EPS:
6.7823
Net Cash Flow:
$9.46B
1W Performance:
-5.42%
1M Performance:
-8.34%
6M Performance:
+20.05%
1Y Performance:
+28.26%
1-Day Range:
$136.44
$139.80
1-Week Range:
$136.44
$146.71
52-Week Range:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
137.34 | 170.50B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
910.55 | 813.11B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.42 | 567.04B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
204.93 | 362.35B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
115.68 | 286.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
184.07 | 285.46B | 58.80B | 10.24B | 8.98B | 3.2788 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
E. Ohman J or Asset Management AB Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos - Fierce Biotech
Gilead Sciences (GILD) Acquires Ouro Medicines for $1.675 Billio - GuruFocus
Gilead Sciences to buy Ouro Medicines to boost T cell therapy for autoimmune diseases (GILD:NASDAQ) - Seeking Alpha
Keymed Biosciences shares rise on $320 mln windfall from Gilead-Ouro deal - Investing.com
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - Stocktwits
Gilead snags another local company, this one launched little more than a year ago - The Business Journals
Gilead boosts immunology pipeline with over $2 billion buyout of Ouro Medicines - WTAQ
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets - WSJ
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports By Reuters - Investing.com
Gilead (GILD) Expands Portfolio with Acquisition of Ouro Medicines - GuruFocus
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal By Reuters - Investing.com
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal - AOL.com
Gilead to buy Ouro Medicines for up to $2.2 billion By Investing.com - Investing.com India
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Gilead Sciences to acquire Ouro Medicines in push for autoimmune disease therapies - Traders Union
Gilead to buy Ouro Medicines for up to $2.2 billion - Investing.com
Gilead to acquire Ouro Medicines for up to $2.18 billion By Investing.com - Investing.com India
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - GlobeNewswire Inc.
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases - TradingView
Gilead to Buy Ouro Medicines for Its Autoimmune Drugs - Bloomberg.com
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases - Business Wire
Gilead nearing $2B takeout of Ouro: report - FirstWord Pharma
Gilead Sciences (GILD) Nears $2 Billion Acquisition of Ouro Medi - GuruFocus
Gilead (GILD) Edges Toward $2 Billion Acquisition of Ouro Medici - GuruFocus
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports - Yahoo Finance
Gilead Sciences nears $2 billion Ouro Medicines acquisition - Investing.com South Africa
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports - marketscreener.com
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines - Financial Times
Gilead boss' compensation jumped 20% last year to $28.4 million - The Business Journals
Weekly Recap: Should I set a stop loss on Gilead Sciences Inc2026 WrapUp & Verified Entry Point Signals - baoquankhu1.vn
Gilead Sciences to Buy Arcellx in $7.8B Deal to Strengthen Cell Therapy Portfolio - The Healthcare Technology Report.
Stock Recap: What is the next catalyst for Gilead Sciences Inc2026 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
GILD.SW Gilead Sciences SIX up 70.33% pre-market 23 Mar 2026: valuation risk - Meyka
Arcellx earnings on deck ahead of Gilead acquisition close - Investing.com
Nordea Investment Management AB Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
New England Research & Management Inc. Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
IAM Advisory LLC Takes $1.27 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BCGM Wealth Management LLC Invests in Gilead Sciences - National Today
BCGM Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Here is what to know beyond why Gilead Sciences, Inc. (GILD) is a trending stock - MSN
Former Gilead Sciences GC To Earn Over $2.5M Severance - Law360
Form DEF 14A GILEAD SCIENCES For: 20 March - Investing.com
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Gilead Ends Obeldesivir Filovirus Prophylaxis Trial: What It Means for GILD Investors - TipRanks
Gilead could potentially end HIV. But will it be able to? - Pharma Voice
Groupama Asset Managment Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Confluence Investment Management LLC Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Anderson Hoagland & Co. Purchases New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
AIA Group Ltd Increases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Mar 16 '26 |
Sale |
144.23 |
3,000 |
432,690 |
179,191 |
0.79%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):